Atomic Alchemy

Cover Block

Name	Atomic Alchemy
Tagline	U.S. radioisotope producer for medical, research, industrial, defense, and space applications.
Headquarters	Idaho Falls, United States
Founded	2018
Stage	Exited
Business Model	B2B
Industry	Deeptech
Technology	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Seed (total disclosed ~$650,000)

Links

• Website: https://www.atomicalchemy.us/
• LinkedIn: https://www.linkedin.com/company/atomic-alchemy-inc

Executive Summary

Atomic Alchemy has built a U.S.-based radioisotope production platform, a bet on domesticating a critical supply chain for medical, industrial, and defense applications that is now strategically validated by its acquisition by advanced fission company Oklo Inc. [American Nuclear Society / Nuclear Newswire, November 2024]. Founded in 2018 by nuclear engineer Thomas Eiden, the company's core differentiation is its proprietary technology for producing isotopes from non-power atomic reactors, a process it aims to scale at a dedicated facility within the Idaho National Laboratory [ANS / Nuclear Newswire, 2025-11-24]. Eiden brings over four decades of engineering and project development experience in the power sector, with a specific focus on reactor design and nuclear systems [LinkedIn, Thomas Eiden, 2026] [thomaseiden.com, Unknown].

Financially, the company's path culminated in an all-stock acquisition by Oklo valued at $25 million, which closed in February 2025 [Businesswire, 20250305]. Prior to the exit, it had raised a seed round from investors including Y Combinator and Oklo [TheCompanyCheck, Unknown]. The business model is B2B, supplying high-value isotopes as a raw material to end-users across healthcare, research, and industry.

The primary near-term catalyst for the combined entity is the pending regulatory approval for its proposed four-reactor production facility. Over the next 12-18 months, execution will hinge on navigating the Nuclear Regulatory Commission licensing process and demonstrating that its integrated production model can achieve cost and reliability advantages over incumbent suppliers.

Data Accuracy: GREEN -- Core facts (acquisition, founder, technology, regulatory filings) are corroborated by multiple independent sources including trade press, corporate announcements, and founder profiles.

Taxonomy Snapshot

Axis	Classification
Stage	Exited
Business Model	B2B
Industry / Vertical	Deeptech
Technology Type	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Seed (total disclosed ~$650,000)

How the Company Got Here

Atomic Alchemy was founded in 2018 by Thomas Eiden, a nuclear engineer with over four decades of experience in power generation and reactor design, to address a persistent shortage in the domestic radioisotope supply chain [Crunchbase]. The company is headquartered in Idaho Falls, Idaho, a location of strategic importance due to its proximity to the Idaho National Laboratory [PitchBook]. The founding vision was to build scalable U.S. production capabilities for essential isotopes used in medicine, research, and industry [Atomic Alchemy].

The company secured a seed investment, reportedly $150,000, in June 2019, with participation from Y Combinator and Oklo [TheCompanyCheck]. A significant regulatory milestone was achieved when the company received a license from the Nuclear Regulatory Commission to handle radium-226 at its Idaho Radiochemistry Laboratory [World Nuclear News]. The company’s trajectory culminated in its acquisition by advanced fission company Oklo Inc. in an all-stock transaction valued at $25 million, which closed on February 28, 2025 [Businesswire, 20250305]. Atomic Alchemy now operates as a subsidiary of Oklo [Nuclear Newswire, November 2024].

Data Accuracy: GREEN -- Company founding and location confirmed by multiple databases; acquisition details confirmed by official press release and trade publication.

Product and Technology

Atomic Alchemy's core product is a domestic supply of radioisotopes. The company's public framing centers on reliability and U.S.-based production, a direct response to documented global shortages [Atomic Alchemy]. Its proprietary VIPR® technology is cited as the method for producing a wide array of these isotopes [Atomic Alchemy].

The operational foundation for this production is a combination of regulatory permissions and planned infrastructure. The company holds a license from the Nuclear Regulatory Commission (NRC) to handle radium-226 at its Idaho Radiochemistry Laboratory [World Nuclear News]. Atomic Alchemy has requested NRC permission to build four nonpower reactors dedicated to radioisotope production at the Idaho National Laboratory [ANS / Nuclear Newswire, November 2024]. This planned 15-MWt light water Versatile Isotope Production Reactor (VIPR) represents the scalable production capability the company has publicly discussed [ANS / Nuclear Newswire, November 2024]. A secondary technical thread involves radioisotope separation from used reactor fuel [Atomic Alchemy].

Data Accuracy: GREEN -- Core product claims and key regulatory/technical milestones are confirmed by company statements and nuclear trade press.

Where the Demand Sits

Metric	Value
Nuclear Medicine Market 2024	$8.8B
Projected CAGR 2024-2030	9.5%
Medical Isotopes Market	$6B

Data Accuracy: YELLOW -- Market sizing is drawn from analogous, published third-party reports for adjacent sectors; specific TAM for domestic radioisotope production is not independently verified.

Competitive Landscape

Atomic Alchemy’s competitive position is defined by its strategic integration into a vertically-focused nuclear platform following its acquisition by Oklo.

• Medical Isotope Production. The primary incumbent suppliers are large, multinational entities like Curium, GE HealthCare, and Lantheus. Their edge is scale and regulatory history, but their vulnerability is supply chain concentration and geopolitical risk.
• Research & Industrial Isotopes. The market is served by a mix of national laboratories and a few specialized commercial producers.
• Advanced Fission Platforms with Isotope Ambitions. Companies like TerraPower and X-energy are developing advanced reactor designs that could, in theory, be configured for isotope co-production.

Atomic Alchemy’s defensible edge today is its focused regulatory and operational execution as a dedicated isotope producer, now backed by Oklo’s resources. The company has secured a specific NRC license for radium-226 processing [World Nuclear News] and has applied to build four dedicated nonpower reactors at Idaho National Laboratory [ANS / Nuclear Newswire, 2025-11-24].

Data Accuracy: YELLOW - Competitive analysis is inferred from market structure and adjacent players; no direct competitor names are cited in primary sources for Atomic Alchemy.

Opportunity

If Atomic Alchemy successfully scales its domestic radioisotope production, it could capture a strategic position in a multi-billion dollar global supply chain that is currently fragmented and reliant on aging foreign reactors.

Metric	Value
Medical Supply Anchor	NRC approval and construction of the first VIPR reactor at Idaho National Lab
Oklo Integration Flywheel	Successful commissioning of Oklo's first commercial power reactor

Data Accuracy: YELLOW -- Key opportunity claims (license application, acquisition value) are confirmed by trade press. Market size and comparable valuation specifics are not publicly detailed by the company.

Sources

1. [American Nuclear Society / Nuclear Newswire, November 2024] Oklo plans to acquire radioisotope firm Atomic Alchemy for $25 million in shares | https://www.ans.org/news/article-5822/oklo-plans-to-acquire-radioisotope-firm-atomic-alchemy-for-25-million-in-shares/
2. [Atomic Alchemy, Unknown] Atomic Alchemy | https://www.atomicalchemy.us/
3. [ANS / Nuclear Newswire, November 2024] Oklo plans to acquire radioisotope firm Atomic Alchemy for $25 million in shares | https://www.ans.org/news/article-6564/oklo-plans-to-acquire-radioisotope-firm-atomic-alchemy-for-25-million-in-shares/
4. [ANS / Nuclear Newswire, 2025-11-24] Oklo plans to acquire radioisotope firm Atomic Alchemy for $25 million in shares | https://www.ans.org/news/article-6564/oklo-plans-to-acquire-radioisotope-firm-atomic-alchemy-for-25-million-in-shares/
5. [Businesswire, 20250305] Oklo Inc. Completes Acquisition of Atomic Alchemy | https://www.businesswire.com/news/home/20250305905605/en/
6. [Crunchbase, Unknown] Atomic Alchemy - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/atomic-alchemy
7. [Crowell & Moring, Unknown] Crowell & Moring Represents Nuclear Energy Startup Atomic Alchemy in its Acquisition by Oklo | https://www.crowell.com/en/insights/firm-news/crowell-and-moring-represents-nuclear-energy-startup-nuclear-energy-startup-atomic-alchemy-in-its-acquisition-by-oklo
8. [Grand View Research, 2024] Nuclear Medicine Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/nuclear-medicine-market
9. [LinkedIn, John Painter, 2026] John Painter - RETIRED | https://www.linkedin.com/in/john-painter-91a13612/
10. [LinkedIn, Thomas Eiden, 2026] Thomas Eiden - Founder & CEO at Atomic Alchemy | https://www.linkedin.com/in/thomas-eiden-0a1b1a1b/
11. [NASA, Unknown] Radioisotope Power Systems | https://rps.nasa.gov/
12. [Nuclear Newswire, November 2024] Oklo plans to acquire radioisotope firm Atomic Alchemy for $25 million in shares | https://www.ans.org/news/article-5822/oklo-plans-to-acquire-radioisotope-firm-atomic-alchemy-for-25-million-in-shares/
13. [PitchBook, Unknown] Atomic Alchemy 2026 Company Profile: Valuation, Investors, Acquisition | https://pitchbook.com/profiles/company/265217-59
14. [TheCompanyCheck, Unknown] ATOMIC ALCHEMY | https://www.thecompanycheck.com/company/atomic-alchemy
15. [thomaseiden.com, Unknown] Thomas Eiden | https://www.thomaseiden.com/
16. [U.S. Department of Energy, Unknown] Isotope Program | https://www.energy.gov/science/isotope-program
17. [World Nuclear Association, Unknown] Medical Isotopes | https://world-nuclear.org/information-library/non-power-nuclear-applications/radioisotopes-research/medical-isotopes.aspx
18. [World Nuclear News, Unknown] Atomic Alchemy receives NRC licence for radium-226 processing | https://world-nuclear-news.org/Articles/Atomic-Alchemy-receives-NRC-licence-for-radium-226